The erection dysfunction market isn't t mattered.

The newest York-based pharmaceutical giant is currently holding a formidable share in the ED medication marketplace as competition from generic drug makers absorbs earnings of its libido treatment, Viagra.

The medication, originally developed with the intention of treating high blood pressure in adults, turned into a hit for males struggling at the sack and Pfizer when it had been introduced to the U. S. market in 1998. Within its first quarter, Viagra brought a total of $400 million in revenue for Pfizer and could later produce annual sales of about $1.8 billion.

Approximately 1 in 10 men suffer from erectile dysfunction, or ED, based on the Cleveland Clinic. Viagra started a previously undiscussed conversation between guys and their doctors about wellbeing and was the first noninvasive remedy for impotency.

Sales of the brand new medication have dropped. Pfizer lost exclusive rights bringing a flood of generic versions. U. S. earnings of”the blue pill” declined 73% year over year at 2018 from $789 million to $217 million, Pfizer said in its own fourth quarter earnings report, since generics entered industry.